Founded

2018

Location

2002 Timberloch Place

The Woodlands, Texas,

United States of America

OUR STORY

Fuzionaire Diagnostics (“Fuzionaire Dx”) is a nuclear medicine company on a mission to improve disease diagnosis and treatment. 

Our patented molecular scaffolds enable efficient, late-stage incorporation of radioisotopes into diagnostic pharmaceuticals. This offers researchers and clinicians a new strategy for improved diagnosis, monitoring, and treatment of numerous diseases, and the acceleration of drug development.

For more, visit us at: www.fuzionairedx.com


OUR TEAM

Nick slavin

Nick Slavin

Co-Founder and CEO

Mr. Slavin is the founding CEO of Fuzionaire and Fuzionaire Diagnostics. His mission is to create a better and more hopeful future. Through the work of Fuzionaire, he is leveraging the power of scientific breakthroughs to solve some of the world’s biggest challenges at scale. Outside of Fuzionaire, Mr. Slavin is the founder and chairman of the Slavin Family Foundation, whose fellowships support some of the world’s top student entrepreneurs, and the founder of EES Ventures, a seed-stage venture capital firm. With Nova Spivack, Mr. Slavin is also a co-founder of the Arch Mission Foundation (AMF), a nonprofit creating repositories of human knowledge and biology in space. AMF launched the first permanent library in solar-orbit in February 2018 in the glove box of Elon Musk’s Tesla Roaster, which was the payload for SpaceX’s Falcon Heavy test flight. In 2019, AMF landed the Lunar Library on the Moon. Previously, Mr. Slavin spent six years at top-ranked law firm Skadden Arps, focusing on public and private mergers and acquisitions. He hold a BA from Yale, magna cum laude and Phi Beta Kappa, where he founded his first company and graduated at 19, and a JD from Harvard Law School. 

Fdx headshot

Christopher Waldmann, PhD

Chief Scientific Officer

Dr. Waldmann is a radiopharmacist and scientist with more than a decade of experience in radiopharmaceutical manufacturing and development. As a postdoc at UCLA’s Crump Institute for Molecular Imaging, Dr. Waldmann invented the HetSiFA technology in collaboration with the laboratory of Nobel Laureate Robert H. Grubbs at Caltech. The invention constitutes the scientific basis of Fuzionaire Diagnostics. He previously was the Head of Radiochemistry at the University Medical Center Mainz, Germany, where he manufactured radiopharmaceuticals for diagnostic and therapeutic applications. Dr. Waldmann continues to be an advisor to the University Medical Center and holds a scientific affiliation there. His research focuses on the development of radiopharmaceuticals for theranostic applications in oncology. He is the author of a chapter in the textbook Molecular Imaging in Oncology, and his work has been published in leading academic journals including Theranostics, PNAS and Nature.

Nove spivack

Nova Spivack

Co-Founder

Mr. Spivack is a serial entrepreneur, technology futurist, and co-founder of the in house incubator of Stanford Research Institute (SRI) and Sarnoff Laboratories, which launched SIRI (acquired by Apple). He is the founder and CEO of the early stage science and technology incubator, Magical, and is co-founder and chairman of the Arch Mission Foundation. Previously, Mr. Spivack was CEO of Bottlenose, a leader in real-time data analytics. He founded Radar Networks in 2003, business incubator Lucid Ventures in 2001, and in 1994 he co-founded EarthWeb, Inc., one of the first web start-ups (record-breaking IPO in 1998) and spinout Dice.com (IPO in 2007). He is also a co-founder or early investor in The Daily Dot, Klout (acquired by Lithium), and a number of applied and life science companies including Space Adventures and Cambrian Genomics. Mr. Spivack is an inventor on nearly 100 granted and pending patents.